HomeREGULATORY
REGULATORY

MHLW Reiterates Caution over Tagrisso Use after Opdivo Treatment
(Jan.26.2018)

The Ministry of Health, Labor and Welfare (MHLW) on January 24 re-stressed the risk of using AstraZeneca’s EGFR tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) in patients who have been treated with Opdivo (nivolumab), repeating its warning first issued in 2016 ...
(LOG IN FOR FULL STORY)

News Calendar